ReviewNuclear medicine and molecular imaging2018
Treatment of Bone Metastasis with Bone-Targeting Radiopharmaceuticals.
Review in Nuclear medicine and molecular imaging, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- A systematic review of [Frontiers in oncology · 2022Pooled it
- [European journal of nuclear medicine and molecular imaging · 2025Trial
- LLMs as emerging tools for understanding and managing bone metastasis and cancer-induced bone pain.iScience · 2026Article
- Cancer Pain: Radiotherapy as a Double-Edged Sword.International journal of molecular sciences · 2025Review
- Bridging the Gap in Understanding Bone Metastasis: A Multifaceted Perspective.International journal of molecular sciences · 2024Review
- Denosumab versus pamidronate in the treatment of osteolytic bone metastases secondary to breast cancer: a multi-institutional analysis.Proceedings (Baylor University. Medical Center) · 2024Article
- TOR1B: a predictor of bone metastasis in breast cancer patients.Scientific reports · 2023Article
- Effect of HMolecules (Basel, Switzerland) · 2023Article
- A Multimodal Clinical Approach for the Treatment of Bone Metastases in Solid Tumors.Anesthesiology and pain medicine · 2022Review
- Monitoring and modulation of the tumor microenvironment for enhanced cancer modeling.Experimental biology and medicine (Maywood, N.J.) · 2022Review
- Dosing Therapeutic Radiopharmaceuticals in Obese Patients.International journal of molecular sciences · 2022Review
- Preparation and characterization of scutellarin loaded on ultradeformable nano-liposomes scutellarin EDTMP (S-UNL-E) and in vitro study of its osteogenesis.Bioengineered · 2022Article
- Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases.Molecules (Basel, Switzerland) · 2021Review
- Added value of hybrid SPECT with CT imaging for predicting poor therapeutic efficacy ofScientific reports · 2020Article
- Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain.Journal of clinical medicine · 2020Review
- Review
- Contribution of Radionuclide Theranostics for Managing Intractable Malignancies.Nuclear medicine and molecular imaging · 2018Article
- Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium.Frontiers in pharmacology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bone is a common metastatic site of cancer. Bone metastasis reduces life expectancy and results in serious symptoms and complications such as bone pain, pathological fractures, and spinal cord compression, decreasing quality of life by restricting sleep and mobility. Treatment for bone metastasis includes drugs (pure analgesics, hormones, cytotoxic chemotherapy, and bisphosphonates, among others), external radiation therapy, surgery, and radionuclide therapy using bone-targeting radiopharmaceuticals. Particulate radiation with α- or β-rays is used as a bone-targeting radiopharmaceutical in radionuclide therapy. β-Emitters have lower energy and a longer range than α-emitters and have less tumoricidal activity and deliver more radiation to adjacent normal tissue. Therefore, the main therapeutic effect of bone-targeting β-emitters such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.